Wykorzystanie spersonalizowanego narzędzia wspomagania decyzji w zarządzaniu aktywnością fizyczną u osób z cukrzycą typu 1 (NEXT)
Pilotażowe badanie Net-IOB & Exercise Toolkit: Randomizowana, krzyżowa ocena doradcy behawioralnego wspomagania decyzji w celu poprawy bezpieczeństwa glikemii podczas i po wysiłku fizycznym u dorosłych z cukrzycą typu 1 (NEXT)
This study evaluates a clinician-facing decision-support toolkit designed to assist adults with type 1 diabetes in preparing for moderate-intensity exercise. The netIOB & Exercise Toolkit (NEXT) integrates recent glucose data and insulin delivery history to provide individualized suggestions regarding exercise timing, insulin adjustments, and carbohydrate intake.
Adults with type 1 diabetes will complete three supervised exercise sessions under different pre-exercise guidance approaches:
(A) published consensus-based standard-of-care guidance, (B) usual personal care routines, and (C) guidance informed by the NEXT Toolkit.
A healthy adult control group will complete a single supervised exercise session to provide comparative physiologic data.
Przegląd badań
Status
Status
Warunki
Warunki
Interwencja / Leczenie
Interwencja / Leczenie
Szczegółowy opis
People with type 1 diabetes frequently experience variable glucose responses before, during, and after physical activity, including exercise-associated hypoglycemia and the need for unplanned carbohydrate intake. Although consensus-based recommendations exist to guide exercise preparation, many individuals continue to rely on trial-and-error strategies that can be burdensome or difficult to generalize across activities.
This study evaluates the netIOB & Exercise Toolkit (NEXT), a software-based, clinician-facing decision-support system intended to contextualize exercise preparation using recent continuous glucose monitoring (CGM) data and insulin delivery history. The Toolkit estimates net insulin-on-board relative to an individual's programmed basal insulin profile and presents structured, non-automated suggestions related to exercise timing, insulin target adjustments, and carbohydrate intake. All decisions remain under clinician and participant control.
The primary study population consists of adults with type 1 diabetes who complete three supervised, moderate-intensity exercise sessions in a randomized, three-period crossover design. Each session is conducted under a different pre-exercise strategy: consensus standard-of-care guidance, usual personal care routines, or guidance informed by the NEXT Toolkit. Sessions are separated by washout periods to minimize physiologic carryover, and glycemic, insulin delivery, and behavioral outcomes are assessed during exercise and for up to 48 hours post-exercise.
In addition, a healthy adult control group completes a single supervised exercise session without pre-exercise glucose or insulin management interventions. This group is included to provide comparative physiologic context for exploratory analyses.
Exploratory analyses will examine relationships between pre-exercise net insulin-on-board (netIOB) strata and glycemic, insulin, and treatment outcomes across exercise sessions. These analyses are intended to characterize patterns of response rather than to test formal efficacy hypotheses.
Participants in both the type 1 diabetes and healthy control groups will wear a commercially available continuous ketone monitoring (CKM) sensor (SiBio KS1) for exploratory data collection during exercise and defined post-exercise monitoring periods. CKM data are collected solely for research purposes, are not used to guide clinical or study-related decisions, and are not intended to evaluate device performance.
The NEXT Toolkit is classified as a non-significant risk, IDE-exempt investigational tool. Results from this pilot study are intended to inform future research design and the development of transparent, open-access methods for studying exercise physiology and glucose management in diabetes.
Typ studiów
Typ studiów
Zapisy (Szacowany)
Zapisy
Faza
Faza
- Nie dotyczy
Kontakty i lokalizacje
Kontakt w sprawie studiów
Kontakt w sprawie studiów
- Nazwa: Ryan Kingman, BS
- Numer telefonu: 650-736-4417
- E-mail: rkingman@stanford.edu
Kopia zapasowa kontaktu do badania
- Nazwa: Dessi Zaharieva, PhD
- Numer telefonu: 628-238-9420
- E-mail: dessi@stanford.edu
Lokalizacje studiów
-
-
California
-
Palo Alto, California, Stany Zjednoczone, 94304
- Rekrutacyjny
- Stanford University
-
Główny śledczy:
- Rayhan Lal, MD
-
Kontakt:
- Ryan Kingman, BS
- Numer telefonu: 650-736-4417
- E-mail: rkingman@stanford.edu
-
Kontakt:
- Dessi Zaharieva, PhD
- Numer telefonu: 628-238-9420
- E-mail: dessi@stanford.edu
-
Pod-śledczy:
- Dessi Zaharieva, PhD
-
-
Kryteria uczestnictwa
Kryteria kwalifikacji
Kryteria kwalifikacji
Wiek uprawniający do nauki
Akceptuje zdrowych ochotników
Płeć kwalifikująca się do nauki
Opis
Inclusion Criteria Inclusion Criteria: All Participants (Type 1 Diabetes and Healthy Control Groups)
- Adults between the age of 18-60 years
- Able to perform moderate intensity walking for 60 minutes (target 40-60% age-predicted maximal heart rate).
- Willing and able to comply with study procedures, including supervised exercise visits and device wear
- Able to provide written informed consent
Inclusion Criteria: Type 1 Diabetes Group Only
- Clinical diagnosis of type 1 diabetes for >1 year, based on the investigator's clinical judgement
- Current use of continuous subcutaneous insulin infusion with Tandem Control-IQ and a compatible continuous glucose monitor (CGM) for >1 month prior to enrollment
- Stable insulin delivery regimen, with no planned changes to insulin pump settings or insulin dosing strategy during the study period
- Consistent CGM use during the month prior to enrollment (>80% data availability)
Inclusion Criteria: Health Control Group Only
- No diagnosis of diabetes or other disorders of glucose metabolism
- Not using insulin or glucose-lowering medications
Exclusion Criteria Exclusion Criteria: All Participants
- Intercurrent illness or medical condition that precludes safe participation in moderate-intensity exercise (e.g., unstable cardiopulmonary disease, uncontrolled arrhythmia, or uncontrolled hypertension), as previously assessed by the participant's primary care physician
- Known coronary artery disease with symptoms limiting moderate physical activity, or history of myocardial infarction, percutaneous coronary intervention, or coronary artery bypass grafting within the past 12 months
- Pregnancy, lactation, or plans to become pregnant during the study period
- Renal insufficiency with estimated GFR <45 mL/min/1.73 m², dialysis dependence, or adrenal insufficiency
- Concurrent participation in another interventional drug or device study within 30 days prior to enrollment
- Inability to comply with study procedures or safety requirements (e.g., inability to achieve target heart-rate zone, attend scheduled visits, or enable required device data access), or otherwise deemed unsuitable by the investigator
Exclusion Criteria: Type 1 Diabetes Group Only
- Use of non-CSII insulin delivery, including long-acting injectable or inhaled insulin, during the study period
- Use of medications with potential to substantially affect glycemia (e.g., SGLT-2 inhibitors, GLP-1 receptor agonists, or GIP agonists), unless on a stable regimen with no planned changes during the study
- Use of systemic corticosteroids within 4 weeks prior to participation
- History of severe hypoglycemia (requiring third-party assistance) or diabetic ketoacidosis within the prior 6 months
Plan studiów
Jak projektuje się badanie?
Szczegóły projektu
- Główny cel: Leczenie podtrzymujące
- Przydział: Randomizowane
- Model interwencyjny: Zadanie krzyżowe
- Maskowanie: Brak (otwarta etykieta)
Liczba ramion
Broń i interwencje
Grupa uczestników / ArmGrupa uczestników / Arm |
Interwencja / LeczenieInterwencja / Leczenie |
|---|---|
|
Inny: Standard-of-Care (SoC)
Participants follow consensus-based guidance for insulin and carbohydrate adjustments around exercise, as outlined in current international standards. These recommendations are applied by study staff in advance of the exercise session. |
Study staff provide insulin and carbohydrate adjustment advice based on consensus exercise management guidelines (Moer et al., 2024), tailored to the planned activity. Continuous glucose monitoring using an FDA-cleared system (Dexcom G7) for research data collection during and after exercise. CGM data are used to assess glycemic responses and are not used to evaluate device performance or accuracy. A commercially available continuous ketone monitoring (CKM) device will be used for exploratory data collection during and after exercise. Ketone data are collected for research purposes only and are not used for clinical decision-making or to evaluate device performance. |
|
Inny: Usual Care (UC)
Participants use their own strategies for managing insulin and carbohydrate around exercise. |
Continuous glucose monitoring using an FDA-cleared system (Dexcom G7) for research data collection during and after exercise. CGM data are used to assess glycemic responses and are not used to evaluate device performance or accuracy. A commercially available continuous ketone monitoring (CKM) device will be used for exploratory data collection during and after exercise. Ketone data are collected for research purposes only and are not used for clinical decision-making or to evaluate device performance. Participants independently manage their insulin and carbohydrate decisions around exercise, using their routine practices without study-provided guidance. |
|
Eksperymentalny: netIOB & Exercise Toolkit (NEXT)
Physicians receive personalized, algorithm-informed recommendations for exercise-related insulin and carbohydrate adjustments. Recommendations are generated using the investigational netIOB & Exercise Toolkit based on CGM data, insulin history, and real-time inputs. |
Continuous glucose monitoring using an FDA-cleared system (Dexcom G7) for research data collection during and after exercise. CGM data are used to assess glycemic responses and are not used to evaluate device performance or accuracy. A commercially available continuous ketone monitoring (CKM) device will be used for exploratory data collection during and after exercise. Ketone data are collected for research purposes only and are not used for clinical decision-making or to evaluate device performance. An investigational software tool generates individualized insulin and carbohydrate adjustment recommendations before and after exercise using CGM data and recent insulin delivery. Study physicians review and relay these recommendations to participants. |
|
Inny: Healthy Control
Adults without diabetes complete one supervised moderate-intensity exercise session for physiologic comparison. |
Continuous glucose monitoring using an FDA-cleared system (Dexcom G7) for research data collection during and after exercise. CGM data are used to assess glycemic responses and are not used to evaluate device performance or accuracy. A commercially available continuous ketone monitoring (CKM) device will be used for exploratory data collection during and after exercise. Ketone data are collected for research purposes only and are not used for clinical decision-making or to evaluate device performance. |
Co mierzy badanie?
Podstawowe miary wyniku
Podstawowe miary wyniku
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Composite Score of Glycemic Safety and Carbohydrate Burden
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
This composite outcome reflects glycemic risk during exercise and the subsequent post-exercise monitoring period. The score is based on a Magni risk-derived metric computed from continuous glucose monitoring (CGM) data, with the glycemic effects of rescue carbohydrate treatments removed to isolate underlying glycemic risk. Each evaluated timepoint is given a score ranging from 0 to 100, where lower scores indicate lower glycemic risk and higher scores indicate higher glycemic risk. Scores across the defined observation windows are summarized across intervention conditions. |
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Miary wyników drugorzędnych
Miary wyników drugorzędnych
Miara wyniku |
Opis środka |
Ramy czasowe |
|---|---|---|
|
Percent-Based Continuous Glucose Monitor Metrics
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Assess standard continuous glucose monitoring (CGM) metrics during defined time windows relative to exercise (0-90 minutes, 0-6 hours, 6-24 hours, and 24-48 hours post-exercise). These include:
|
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
|
Glucose Concentration and Variability Metrics from Continuous Glucose Monitor
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Mean glucose level, glucose standard deviation (SD), and coefficient of variation (CV) will be calculated using CGM data collected over defined time periods relative to exercise. These metrics describe overall glycemic variability and will be used to assess the stability of glucose control following each intervention. Units of Measure: Mean glucose: mg/dL SD: mg/dL CV: % |
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
|
Frequency of Hypoglycemic Events
Ramy czasowe: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
Number of hypoglycemic episodes per participant at thresholds of <70 mg/dL and <54 mg/dL, stratified by treatment arm. Events will be classified as treated or untreated. |
Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
|
Glucose Nadir Value
Ramy czasowe: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
Lowest glucose value (nadir mg/dl) recorded per participant during exercise period and 0-6 hours post-exercise, as measured by CGM. |
Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
|
Time to First Hypoglycemic Event
Ramy czasowe: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
Time (in minutes) from exercise start to the first hypoglycemic episode (<70 mg/dL) for each participant. |
Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise); total of 7.5 hours per visit (3 visits).
|
|
Carbohydrate Consumption for Hypoglycemia Prevention/Treatment
Ramy czasowe: Exercise (0 to 90 minutes); total of 1.5 hours per visit (3 visits).
|
Quantify carbohydrate use related to exercise using:
|
Exercise (0 to 90 minutes); total of 1.5 hours per visit (3 visits).
|
|
Total and Programmed Insulin Delivery
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Compare the total insulin delivered (actual) to the amount that would have been delivered based on the participant's pre-programmed basal rates. This includes both basal and bolus insulin. |
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
|
Frequency of User-Initiated Pump Adjustments
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Number of times participants manually modified insulin delivery during the exercise period, including suspensions, temporary targets, exercise mode, or basal rate changes. |
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
|
Duration of User-Initiated Pump Adjustments
Ramy czasowe: Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
Cumulative duration of user-initiated pump modifications, including time spent in temporary targets, pump suspensions, and exercise modes. |
Baseline (1 hour pre-exercise), Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise), Mid Post-Exercise (6 to 24 hours after exercise), Late Post-Exercise (24 to 48 hours after exercise); total of 50.5 hours per visit (3 visits).
|
|
Baseline and Peak Ketone Levels
Ramy czasowe: Baseline (immediately prior to exercise) and Exercise (0 to 90 minutes from exercise).
|
Baseline and peak ketone concentrations (mmol/L) measured using continuous ketone monitoring during the exercise period. Outcomes will be explored across pre-exercise strategies in participants with type 1 diabetes and relative to healthy control participants. |
Baseline (immediately prior to exercise) and Exercise (0 to 90 minutes from exercise).
|
|
Ketone Exposure (AUC) During and After Exercise
Ramy czasowe: Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise) per visit.
|
Ketone exposure quantified as area under the curve (AUC) from continuous ketone monitoring during exercise (0-90 minutes from exercise start) and early post-exercise (0-6 hours after exercise). Outcomes will be explored across pre-exercise strategies in participants with type 1 diabetes and relative to healthy control participants. |
Exercise (0 to 90 minutes), Early Post-Exercise (0 to 6 hours after exercise) per visit.
|
Współpracownicy i badacze
Sponsor
Sponsor
Współpracownicy
Współpracownicy
Śledczy
Śledczy
- Główny śledczy: Rayhan Lal, MD, Stanford University
- Dyrektor Studium: Dessi dessi@stanford.edu, PhD, Stanford University
Daty zapisu na studia
Główne daty studiów
Rozpoczęcie studiów (Rzeczywisty)
Rozpoczęcie studiów
Zakończenie podstawowe (Szacowany)
Zakończenie podstawowe
Ukończenie studiów (Szacowany)
Ukończenie studiów
Daty rejestracji na studia
Pierwszy przesłany
Pierwszy przesłany
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy przesłany, który spełnia kryteria kontroli jakości
Pierwszy wysłany (Rzeczywisty)
Pierwszy wysłany
Aktualizacje rekordów badań
Ostatnia wysłana aktualizacja (Rzeczywisty)
Ostatnia wysłana aktualizacja
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości
Ostatnia weryfikacja
Ostatnia weryfikacja
Więcej informacji
Terminy związane z tym badaniem
Słowa kluczowe
Dodatkowe istotne warunki MeSH
- Choroby układu hormonalnego
- Choroby metaboliczne
- Choroby Autoimmunologiczne
- Choroby układu odpornościowego
- Zaburzenia metabolizmu glukozy
- Cukrzyca
- Zachowanie
- Choroby żywieniowe i metaboliczne
- Cukrzyca typu 1
- Aktywność silnika
- Techniki śledcze
- Techniki laboratoryjne kliniczne
- Techniki i procedury diagnostyczne
- Diagnoza
- Analiza chemiczna krwi
- Testy chemii klinicznej
- Techniki diagnostyczne, hormonalne
- Monitorowanie, fizjologiczne
- Ciągłe monitorowanie glukozy
Inne numery identyfikacyjne badania
Inne numery identyfikacyjne badania
- 82224
- 2407-07175 (Inny numer grantu/finansowania: Leona M & Harry B Helmsley Charitable Trust)
Plan dla danych uczestnika indywidualnego (IPD)
Planujesz udostępniać dane poszczególnych uczestników (IPD)?
Opis planu IPD
De-identified individual participant-level data will be shared, including:
- Continuous glucose monitoring (CGM) metrics from the Dexcom G7 (e.g., time in range, time below/above range, mean glucose, glucose variability)
- Carbohydrate treatment data (timing, amount, type)
- Insulin delivery data (e.g., pump settings, suspensions, automated adjustments)
- Demographic information (e.g., age range, sex, diabetes duration)
IPD that will not be shared includes:
- Direct identifiers (e.g., names, exact dates of birth, addresses)
- Free-text responses or notes containing potentially identifiable information
- Any raw data not essential to the reported outcomes or secondary analyses
Ramy czasowe udostępniania IPD
Data will be available beginning 18 months after article publication and ending 5 years following article publication.
Kryteria dostępu do udostępniania IPD
Proposals should be directed to dessi@stanford.edu. To gain access, data requestors will need to sign a data access agreement.
Typ informacji pomocniczych dotyczących udostępniania IPD
- PROTOKÓŁ BADANIA
- SOK ROŚLINNY
Informacje o lekach i urządzeniach, dokumenty badawcze
Bada produkt leczniczy regulowany przez amerykańską FDA
Bada produkt urządzenia regulowany przez amerykańską FDA
produkt wyprodukowany i wyeksportowany z USA
Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .